R
Reyes Bernabe Caro
Researcher at Services Hospital
Publications - 38
Citations - 2347
Reyes Bernabe Caro is an academic researcher from Services Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 16 publications receiving 961 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann,Luis Paz-Ares,Reyes Bernabe Caro,B. Zurawski,Sang-We Kim,Enric Carcereny Costa,Keunchil Park,A. Alexandru,L. Lupinacci,Emmanuel de la Mora Jimenez,Hiroshi Sakai,Istvan Albert,Alain Vergnenegre,Solange Peters,Konstantinos N. Syrigos,Fabrice Barlesi,Martin Reck,Hossein Borghaei,Julie R. Brahmer,Kenneth J. O'Byrne,William J. Geese,Prabhu Bhagavatheeswaran,Sridhar K. Rabindran,Ravi S. Kasinathan,F. E. Nathan,Suresh S. Ramalingam +25 more
TL;DR: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level.
Journal ArticleDOI
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio,Ernest Nadal,A. Insa,M.-R. García-Campelo,Joaquín Casal-Rubio,Manuel Domine,Margarita Majem,Delvys Rodriguez-Abreu,Alex Martinez-Marti,Javier de Castro Carpeño,Manuel Cobo,Guillermo López Vivanco,Edel del Barco,Reyes Bernabe Caro,Nuria Viñolas,Isidoro Barneto Aranda,Santiago Viteri,E. Pereira,Ana Royuela,M. Casarrubios,Clara Salas Antón,Edwin Roger Parra,Ignacio I. Wistuba,Virginia Calvo,Raquel Laza-Briviesca,Atocha Romero,Bartomeu Massuti,Alberto Cruz-Bermúdez +27 more
TL;DR: The results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC and could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable.
Journal ArticleDOI
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz-Ares,Suresh S. Ramalingam,Tudor-Eliade Ciuleanu,Jong Seok Lee,László Urbán,Reyes Bernabe Caro,Keunchil Park,Hiroshi Sakai,Yuichiro Ohe,Makoto Nishio,Clarisse Audigier-Valette,Jacobus A. Burgers,Adam Pluzanski,Randeep Sangha,Carlos Gallardo,Masayuki Takeda,Helena Linardou,L. Lupinacci,Ki Hyeong Lee,Claudia Caserta,Mariano Provencio,Enric Carcereny,Gregory A. Otterson,Michael Schenker,B. Zurawski,A. Alexandru,A. Vergnenegre,Judith Raimbourg,Kynan Feeney,Sang-We Kim,Hossein Borghaei,Kenneth J. O'Byrne,Matthew D. Hellmann,Arteid Memaj,F. E. Nathan,Judith Bushong,Phuong Tran,Julie R. Brahmer,Martin Reck +38 more
TL;DR: For example, CheckMate 227 as discussed by the authors showed that nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% or less than 1% (prespecified descriptive analysis).
Journal ArticleDOI
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Suresh S. Ramalingam,Tudor Ciuleanu,Adam Pluzanski,Jong Seok Lee,Michael Schenker,Reyes Bernabe Caro,Ki Hyeong Lee,B. Zurawski,Clarisse Audigier-Valette,Mariano Provencio,Helena Linardou,Sang-We Kim,Hossein Borghaei,Matthew D. Hellmann,Kenneth J. O'Byrne,Luis Paz-Ares,Martin Reck,F. E. Nathan,Julie R. Brahmer +18 more
TL;DR: 1L NIVO + IPI significantly improved overall survival compared with chemo in treatment-naive patients in phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo).
Journal ArticleDOI
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
Mariano Provencio,Roberto Serna-Blasco,Ernest Nadal,A. Insa,M.-R. García-Campelo,J. Casal Rubio,Manuel Domine,Margarita Majem,Delvys Rodriguez-Abreu,Alex Martinez-Marti,Javier de Castro Carpeño,Manuel Cobo,Guillermo López Vivanco,Edel del Barco,Reyes Bernabe Caro,Nuria Viñolas,Isidoro Barneto Aranda,Santiago Viteri,E. Pereira,Ana Royuela,Virginia Calvo,Javier Martín-López,F. García-García,M. Casarrubios,Fernando Franco,Estela Sánchez-Herrero,Bartomeu Massuti,Alberto Cruz-Bermúdez,Atocha Romero +28 more
TL;DR: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year overall survival and ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.